OBJECTIVES: The goal of the present study was to analyze prescription patterns and costs of migraine treatment in general (GPs) and neurological practices (NPs) in Germany. METHODS: This study included 43,149 patients in GPs and 13,674 patients in NPs who were diagnosed with migraine in 2015. Eight different families of migraine therapy were included in the analysis: triptans, analgesics, antiemetics, betablockers, antivertigo products, gastroprokinetics, antiepileptics and other medications (all other classes used in the treatment of migraine including homoeopathic medications). The share of migraine therapies and their costs were estimated in GPs and NPs. RESULTS: Mean age was equal to 44.4 years in GPs and to 44.1 years in NPs. Triptans and analgesics were the two most prescribed families of drugs in all patients and in the nine specific subgroups. Interestingly, triptans were more prescribed in NPs compared to GPs (30.9%-55.0% against 30.0%-44.7%), whereas analgesics were less frequently given in NPs than in GPs (11.5%-17.2% against 35.3%-42.4%). Finally, the share of patients with no therapy was higher in NPs compared to GPs (33.9%-58.4% against 27.5%-37.9%). The annual cost per patient was equal to 66.04€ in GPs and to 94.71€ in NPs. Finally, the annual cost per patient increased with age, and was higher in women and in individuals with private health insurance compared to men and individuals with public health insurance, respectively. CONCLUSIONS: Triptans and analgesics were the two most prescribed migraine drugs. Furthermore, approximatively 30%-40% of patients received no therapy. Finally, the annual cost per patient was higher in NPs compared to GPs.